{"id":"tio","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dry mouth"},{"rate":"2-5","effect":"Tremor"},{"rate":"2-5","effect":"Headache"},{"rate":"1-2","effect":"Urinary retention"},{"rate":"1-3","effect":"Constipation"}]},"_chembl":null,"_dailymed":{"setId":"02e24443-04c6-4b98-a395-49aec4a468de","title":"VENXXIVA (TIOPRONIN) TABLET, DELAYED RELEASE [CYCLE PHARMACEUTICALS LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tiotropium binds to muscarinic M3 receptors on airway smooth muscle cells, preventing acetylcholine-induced bronchoconstriction. This results in sustained bronchodilation lasting 24 hours or longer, allowing once-daily dosing. The drug is inhaled directly to the lungs, providing local therapeutic effect with minimal systemic exposure.","oneSentence":"Tiotropium is a long-acting anticholinergic bronchodilator that blocks muscarinic M3 receptors in airway smooth muscle to produce sustained airway relaxation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:09:20.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"},{"name":"Asthma maintenance treatment (in combination with inhaled corticosteroids)"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT03980769","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-05","conditions":"Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder","enrollment":40},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT04708054","phase":"PHASE2, PHASE3","title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-21","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome","enrollment":324},{"nctId":"NCT02861417","phase":"PHASE2","title":"Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-08-05","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome","enrollment":204},{"nctId":"NCT03864016","phase":"NA","title":"Ability of Pupillometry to Reduce Sufentanil Consumption in Planned Cardiac Surgery: Randomized, Controlled, Single-center Clinical Superiority Trial","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-03-20","conditions":"Patients Undergoing Cardiac Surgery, Patients With Coronary Artery Bypass Surgery With CEC","enrollment":50},{"nctId":"NCT07366099","phase":"NA","title":"Al18F-NOTA-LM3 PET/CT in Patients With TIO","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-03-30","conditions":"Tumor-Induced Osteomalacia","enrollment":40},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT06013423","phase":"PHASE2","title":"Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-07-23","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT04783428","phase":"","title":"Tumor-induced Osteomalacia Disease Monitoring Program","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2022-01-31","conditions":"Tumor-induced Osteomalacia (TIO)","enrollment":23},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT06195891","phase":"PHASE1","title":"Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-05-24","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT04859946","phase":"PHASE2","title":"Itacitinib for the Prevention of Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-01-11","conditions":"Hematologic and Lymphocytic Disorder","enrollment":31},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT04530487","phase":"PHASE2","title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-19","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor","enrollment":1},{"nctId":"NCT02220985","phase":"PHASE2","title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2015-02-03","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":84},{"nctId":"NCT04973176","phase":"NA","title":"Standard Versus Flexible Tip Bougie for Videolaryngoscopy","status":"COMPLETED","sponsor":"University Hospitals Coventry and Warwickshire NHS Trust","startDate":"2021-08-23","conditions":"Intubation, Intratracheal","enrollment":160},{"nctId":"NCT03775187","phase":"","title":"Expanded Access to Burosumab","status":"AVAILABLE","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"","conditions":"X-linked Hypophosphatemia, Tumor-Induced Osteomalacia","enrollment":""},{"nctId":"NCT00554788","phase":"PHASE3","title":"Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-05-06","conditions":"Extraocular Retinoblastoma","enrollment":60},{"nctId":"NCT05393245","phase":"","title":"Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19467},{"nctId":"NCT04521946","phase":"PHASE1","title":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-14","conditions":"Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Germ Cell Tumor","enrollment":""},{"nctId":"NCT05402020","phase":"","title":"Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":17018},{"nctId":"NCT05357573","phase":"PHASE4","title":"Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2022-09-07","conditions":"Tumor-Induced Osteomalacia (TIO)","enrollment":9},{"nctId":"NCT02304367","phase":"PHASE2","title":"Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2015-03-24","conditions":"Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS)","enrollment":17},{"nctId":"NCT00653068","phase":"PHASE3","title":"Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-02-10","conditions":"Childhood Atypical Teratoid/Rhabdoid Tumor","enrollment":70},{"nctId":"NCT05164640","phase":"NA","title":"Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry\"","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2021-12-01","conditions":"Cardiac Ischemia","enrollment":200},{"nctId":"NCT01858740","phase":"PHASE2","title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2014-04-10","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":20},{"nctId":"NCT05127304","phase":"","title":"A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-02-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":11316},{"nctId":"NCT04320316","phase":"PHASE4","title":"A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-07-31","conditions":"Epidermal Nevus Syndrome","enrollment":1},{"nctId":"NCT00567567","phase":"PHASE3","title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-11-05","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":665},{"nctId":"NCT00867178","phase":"PHASE1","title":"Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-02-25","conditions":"Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":33},{"nctId":"NCT04926233","phase":"","title":"Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1371146},{"nctId":"NCT04184297","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":27190},{"nctId":"NCT04402515","phase":"","title":"Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2021-10-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT03084796","phase":"PHASE2","title":"A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":733},{"nctId":"NCT02676089","phase":"PHASE3","title":"TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-04-06","conditions":"Asthma","enrollment":1433},{"nctId":"NCT03510455","phase":"PHASE2","title":"BGJ398 for the Treatment of Tumor-Induced Osteomalacia","status":"TERMINATED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2019-02-27","conditions":"Tumor-Induced Osteomalacia, Oncogenic Osteomalacia","enrollment":4},{"nctId":"NCT04689893","phase":"PHASE1","title":"Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-15","conditions":"Tumor-Induced Osteomalacia","enrollment":50},{"nctId":"NCT03731494","phase":"","title":"Quality of Life in Systemic Nickel Allergy Syndrome","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2015-03","conditions":"Systemic Nickel Allergy Syndrome, Quality of Life","enrollment":52},{"nctId":"NCT02850978","phase":"","title":"Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-08-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1335},{"nctId":"NCT03376295","phase":"","title":"Comparative Effectiveness of COPD Treatments","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-12-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3954},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT00565266","phase":"PHASE3","title":"Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-05","conditions":"Asthma","enrollment":210},{"nctId":"NCT02799784","phase":"PHASE4","title":"An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-07-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT00099762","phase":"","title":"Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia","status":"COMPLETED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2004-12-15","conditions":"Osteomalacia, Neoplasms","enrollment":45},{"nctId":"NCT01331694","phase":"","title":"Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76130},{"nctId":"NCT01381406","phase":"","title":"Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3333},{"nctId":"NCT00706446","phase":"NA","title":"The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-06","conditions":"Asthma","enrollment":255},{"nctId":"NCT01381458","phase":"","title":"Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1936},{"nctId":"NCT01387178","phase":"","title":"Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22223},{"nctId":"NCT01395875","phase":"","title":"Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2849},{"nctId":"NCT02244580","phase":"NA","title":"Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit \"MammaTyperTM\"","status":"COMPLETED","sponsor":"BioNTech Diagnostics GmbH","startDate":"2014-08","conditions":"Invasive Breast Cancer","enrollment":1010},{"nctId":"NCT01255917","phase":"","title":"Nerve Growth Factor in Chronic Pancreatitis","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2008-02","conditions":"Chronic Pancreatitis","enrollment":38},{"nctId":"NCT01040403","phase":"PHASE2","title":"Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":233},{"nctId":"NCT00168831","phase":"PHASE3","title":"Tiotropium / Respimat One-Year Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1007},{"nctId":"NCT00168844","phase":"PHASE3","title":"Tiotropium / Respimat One-Year Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":983},{"nctId":"NCT00496470","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":660}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34571,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Spiriva®"],"phase":"marketed","status":"active","brandName":"TIO","genericName":"TIO","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tiotropium is a long-acting anticholinergic bronchodilator that blocks muscarinic M3 receptors in airway smooth muscle to produce sustained airway relaxation. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment (in combination with inhaled corticosteroids).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}